Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

KI YOUNG CHUNG

Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology

NPI
1336110113
CMS profile
15168
Location
SPARTANBURG, SC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$10,646.94

157 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2025 · entire year · sorted by reported total

Nature of paymentAmountRecords
Consulting Fee $5,870.00 2
Food and Beverage $3,775.07 144
Long term medical supply or device loan $581.83 6
Education $420.04 5

By paying entity

PY2025 · entire year · sorted by reported total

Page 2 of 4; records 51–100 of 157 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

KI YOUNG CHUNG

NPI 1336110113 · CMS profile ID 15168

Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology

SPARTANBURG, SC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 4; records 51–100 of 157 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1336110113?year=2025&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
KI YOUNG CHUNG, NPI 1336110113, CMS profile ID 15168. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 4; records 51–100 of 157 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1336110113?year=2025&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). KI YOUNG CHUNG, NPI 1336110113, CMS profile ID 15168. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 4; records 51–100 of 157 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1336110113?year=2025&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
KI YOUNG CHUNG, NPI 1336110113, CMS profile ID 15168, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 4; records 51–100 of 157 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1336110113?year=2025&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

157 matching records · $10,646.94 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 157 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 157.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Azurity Pharmaceuticals, Inc. $21.8108/20/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1242669458 CMS
Merck Sharp & Dohme LLC $34.3408/13/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1238303519 CMS
PFIZER INC. $20.5408/12/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1231674365 CMS
Daiichi Sankyo Inc. $23.1908/06/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1197018177 CMS
Gilead Sciences, Inc. $121.8708/05/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1234387552 CMS
Celgene Corporation $22.2507/31/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1184570577 CMS
Novartis Pharmaceuticals Corporation $8.6907/30/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1200128971 CMS
GlaxoSmithKline, LLC. $67.0007/29/2025 Education No dispute reported Delay: No
Change: NEW
06/30/2026 1190386259 CMS
Pharmacosmos Therapeutics Inc. $15.9507/29/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1250726369 CMS
Caris MPI, Inc. $33.3907/28/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1234279298 CMS
Azurity Pharmaceuticals, Inc. $18.7207/23/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1242669456 CMS
E.R. Squibb & Sons, L.L.C. $3,820.0007/22/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1184570561 CMS
Lilly USA, LLC $13.0107/22/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1186664143 CMS
Rigel Pharmaceuticals, Inc. $19.8607/21/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1247375696 CMS
AstraZeneca Pharmaceuticals LP $20.9907/17/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1206282670 CMS
Aimmune Therapeutics, Inc. $14.3607/16/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1249717325 CMS
Lilly USA, LLC $23.1707/16/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1186746579 CMS
Eisai Inc. $18.0007/15/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1244491920 CMS
Novartis Pharmaceuticals Corporation $17.9507/14/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1200128969 CMS
PFIZER INC. $21.9107/10/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1231583521 CMS
Janssen Biotech, Inc. $18.7007/09/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1174782059 CMS
Merck Sharp & Dohme LLC $21.3607/08/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1238173084 CMS
E.R. Squibb & Sons, L.L.C. $11.1607/02/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1184570573 CMS
Janssen Biotech, Inc. $24.7107/01/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1174783581 CMS
Bayer Healthcare Pharmaceuticals Inc. $19.8306/26/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1225497174 CMS
Genentech USA, Inc. $53.4506/26/2025 Education No dispute reported Delay: No
Change: NEW
06/30/2026 1211531662 CMS
AstraZeneca Pharmaceuticals LP $20.6206/24/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1206364820 CMS
ABBVIE INC. $16.9606/23/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1201663929 CMS
Janssen Biotech, Inc. $20.3206/19/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1174781784 CMS
Gilead Sciences, Inc. $31.2006/18/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1234431686 CMS
Merck Sharp & Dohme LLC $22.0506/18/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1238349750 CMS
Daiichi Sankyo Inc. $17.4606/17/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1197101713 CMS
Novartis Pharmaceuticals Corporation $83.3306/12/2025 Long term medical supply or device loan No dispute reported Delay: No
Change: NEW
06/30/2026 1200128917 CMS
Novartis Pharmaceuticals Corporation $24.0406/12/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1200128965 CMS
Novartis Pharmaceuticals Corporation $0.8806/12/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1200128967 CMS
Merck Sharp & Dohme LLC $32.9706/11/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1238173112 CMS
Gilead Sciences, Inc. $29.2006/10/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1234443201 CMS
Gilead Sciences, Inc. $0.2806/10/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1234610821 CMS
PFIZER INC. $18.9006/09/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1231627433 CMS
TOLMAR, INC. $33.7306/05/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1237005213 CMS
AstraZeneca Pharmaceuticals LP $18.3606/04/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1206882467 CMS
Genmab U.S., Inc. $121.8706/03/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1235921446 CMS
AstraZeneca Pharmaceuticals LP $19.3805/29/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1206220232 CMS
Eisai Inc. $20.5005/28/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1244491918 CMS
AstraZeneca Pharmaceuticals LP $2,050.0005/21/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1207304282 CMS
Daiichi Sankyo Inc. $23.3405/21/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1197098723 CMS
Janssen Biotech, Inc. $99.9505/15/2025 Education No dispute reported Delay: No
Change: NEW
06/30/2026 1174782130 CMS
Novartis Pharmaceuticals Corporation $99.7005/15/2025 Long term medical supply or device loan No dispute reported Delay: No
Change: NEW
06/30/2026 1200128913 CMS
TAIHO ONCOLOGY, INC. $20.4105/13/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1211407581 CMS
Takeda Pharmaceuticals U.S.A., Inc. $17.9305/12/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1223839981 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $6,662.86 22
PY2020 $2,456.45 9
PY2021 $2,379.01 10
PY2022 $3,311.65 41
PY2023 $11,861.68 146
PY2024 $11,246.64 172
PY2025 $10,646.94 157

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $627,547.51 52
PY2024 Principal investigator $1,192,196.50 37
PY2023 Principal investigator $730,279.90 32
PY2022 Principal investigator $1,530,194.34 54
PY2021 Principal investigator $106,782.01 27
PY2020 Principal investigator $142,607.48 58
PY2019 Recipient $44.41 1
PY2019 Principal investigator $342,856.70 71

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

52 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Coherus Oncology, Inc. $7,308.00 12/23/2025 Covered Recipient Teaching Hospital
Ghs Greenville Memorial Hospital
CHS11402 No dispute reported 06/30/2026 1235252521
Principal investigator 1 PFIZER INC. $60,090.00 12/05/2025 Covered Recipient Teaching Hospital
Ghs Greenville Memorial Hospital
A PHASE 2 BASKET STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB IN SUBJECTS WITH PREVIOUSLY TREATED LOCALLYADVANCED UNRESECTABLE OR METASTATIC SOLID TUMORS DRIVEN BY HER2 ALTERATIONS No dispute reported 06/30/2026 1228738646
Principal investigator 1 AstraZeneca Pharmaceuticals LP $22,850.00 10/29/2025 Covered Recipient Teaching Hospital
Ph Patewood Hospital
A Phase 3 Study of Trastuzumab Deruxtecan (T-DXd) and Rilvegostomig versus Standard-of-Care gemcitabine, cisplatin, and durvalumab for first line locally advanced or metastatic HER2-expressing Biliary Tract Cancer No dispute reported 06/30/2026 1185539417
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $1,109.85 10/27/2025 Non-covered Recipient Entity
Institute For Translational Oncology Research
Phase I open-label, dose escalation trial of BI 1831169 monotherapy and in combination with an anti-PD-1 mAb in patients with advanced or metastatic solid tumors No dispute reported 06/30/2026 1220995014
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $29.30 10/27/2025 Non-covered Recipient Entity
Institute For Translational Oncology Research
Phase I open-label, dose escalation trial of BI 1831169 monotherapy and in combination with an anti-PD-1 mAb in patients with advanced or metastatic solid tumors No dispute reported 06/30/2026 1220995016
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $2.20 10/27/2025 Non-covered Recipient Entity
Institute For Translational Oncology Research
Phase I open-label, dose escalation trial of BI 1831169 monotherapy and in combination with an anti-PD-1 mAb in patients with advanced or metastatic solid tumors No dispute reported 06/30/2026 1220995018
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $373.12 10/27/2025 Non-covered Recipient Entity
Institute For Translational Oncology Research
Phase I open-label, dose escalation trial of BI 1831169 monotherapy and in combination with an anti-PD-1 mAb in patients with advanced or metastatic solid tumors No dispute reported 06/30/2026 1220995020
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $79.92 10/27/2025 Non-covered Recipient Entity
Institute For Translational Oncology Research
Phase I open-label, dose escalation trial of BI 1831169 monotherapy and in combination with an anti-PD-1 mAb in patients with advanced or metastatic solid tumors No dispute reported 06/30/2026 1220995022
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $584.00 10/27/2025 Non-covered Recipient Entity
Institute For Translational Oncology Research
Phase I open-label, dose escalation trial of BI 1831169 monotherapy and in combination with an anti-PD-1 mAb in patients with advanced or metastatic solid tumors No dispute reported 06/30/2026 1220995024
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $916.05 10/27/2025 Non-covered Recipient Entity
Institute For Translational Oncology Research
Phase I open-label, dose escalation trial of BI 1831169 monotherapy and in combination with an anti-PD-1 mAb in patients with advanced or metastatic solid tumors No dispute reported 06/30/2026 1220995026
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $72.32 10/27/2025 Non-covered Recipient Entity
Institute For Translational Oncology Research
Phase I open-label, dose escalation trial of BI 1831169 monotherapy and in combination with an anti-PD-1 mAb in patients with advanced or metastatic solid tumors No dispute reported 06/30/2026 1220995028
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $1,448.55 10/27/2025 Non-covered Recipient Entity
Institute For Translational Oncology Research
Phase I open-label, dose escalation trial of BI 1831169 monotherapy and in combination with an anti-PD-1 mAb in patients with advanced or metastatic solid tumors No dispute reported 06/30/2026 1220995030
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $3.00 10/27/2025 Non-covered Recipient Entity
Institute For Translational Oncology Research
Phase I open-label, dose escalation trial of BI 1831169 monotherapy and in combination with an anti-PD-1 mAb in patients with advanced or metastatic solid tumors No dispute reported 06/30/2026 1220995032
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $25.00 10/27/2025 Non-covered Recipient Entity
Institute For Translational Oncology Research
Phase I open-label, dose escalation trial of BI 1831169 monotherapy and in combination with an anti-PD-1 mAb in patients with advanced or metastatic solid tumors No dispute reported 06/30/2026 1220995034
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $8.80 10/27/2025 Non-covered Recipient Entity
Institute For Translational Oncology Research
Phase I open-label, dose escalation trial of BI 1831169 monotherapy and in combination with an anti-PD-1 mAb in patients with advanced or metastatic solid tumors No dispute reported 06/30/2026 1220995036
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $15.00 10/27/2025 Non-covered Recipient Entity
Institute For Translational Oncology Research
Phase I open-label, dose escalation trial of BI 1831169 monotherapy and in combination with an anti-PD-1 mAb in patients with advanced or metastatic solid tumors No dispute reported 06/30/2026 1220995038
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $56.40 10/27/2025 Non-covered Recipient Entity
Institute For Translational Oncology Research
Phase I open-label, dose escalation trial of BI 1831169 monotherapy and in combination with an anti-PD-1 mAb in patients with advanced or metastatic solid tumors No dispute reported 06/30/2026 1220995040
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $52.50 10/27/2025 Non-covered Recipient Entity
Institute For Translational Oncology Research
Phase I open-label, dose escalation trial of BI 1831169 monotherapy and in combination with an anti-PD-1 mAb in patients with advanced or metastatic solid tumors No dispute reported 06/30/2026 1220995042
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $61.50 10/27/2025 Non-covered Recipient Entity
Institute For Translational Oncology Research
Phase I open-label, dose escalation trial of BI 1831169 monotherapy and in combination with an anti-PD-1 mAb in patients with advanced or metastatic solid tumors No dispute reported 06/30/2026 1220995044
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $11.50 10/27/2025 Non-covered Recipient Entity
Institute For Translational Oncology Research
Phase I open-label, dose escalation trial of BI 1831169 monotherapy and in combination with an anti-PD-1 mAb in patients with advanced or metastatic solid tumors No dispute reported 06/30/2026 1220995046
Principal investigator 1 Boehringer Ingelheim International GmbH $325.57 10/01/2025 Non-covered Recipient Entity
Institute For Translational Oncology Research
Phase I open-label, dose escalation trial of BI 1831169 monotherapy and in combination with an anti-PD-1 mAb in patients with advanced or metastatic solid tumors No dispute reported 06/30/2026 1220643194
Principal investigator 1 Ipsen Biopharmaceuticals, Inc $3,404.00 09/12/2025 Covered Recipient Teaching Hospital
Oconee Memorial Hospital
A Phase II Study of Tazemetostat in Solid Tumors Harboring an ARID1A Mutation No dispute reported 06/30/2026 1184285761
Principal investigator 1 BioNTech SE $270.00 09/10/2025 Covered Recipient Teaching Hospital
Ghs Greenville Memorial Hospital
BNT321-02 No dispute reported 06/30/2026 1249018400
Principal investigator 1 BioNTech SE $90.00 09/10/2025 Covered Recipient Teaching Hospital
Ghs Greenville Memorial Hospital
BNT321-02 No dispute reported 06/30/2026 1249018402
Principal investigator 1 BioNTech SE $1,500.00 09/10/2025 Covered Recipient Teaching Hospital
Ghs Greenville Memorial Hospital
BNT321-02 No dispute reported 06/30/2026 1249018404
Principal investigator 1 BioNTech SE $1,994.00 07/14/2025 Covered Recipient Teaching Hospital
Ghs Greenville Memorial Hospital
BNT321-02 No dispute reported 06/30/2026 1249018406
Principal investigator 1 BioNTech SE $250.00 07/14/2025 Covered Recipient Teaching Hospital
Ghs Greenville Memorial Hospital
BNT321-02 No dispute reported 06/30/2026 1249018408
Principal investigator 1 Coherus Oncology, Inc. $20,200.00 06/26/2025 Covered Recipient Teaching Hospital
Ghs Greenville Memorial Hospital
CHS38802 No dispute reported 06/30/2026 1235252559
Principal investigator 1 PFIZER INC. $21,880.00 05/20/2025 Non-covered Recipient Entity
Prisma Health Cancer Institute
A PHASE 2 BASKET STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB IN SUBJECTS WITH PREVIOUSLY TREATED LOCALLYADVANCED UNRESECTABLE OR METASTATIC SOLID TUMORS DRIVEN BY HER2 ALTERATIONS No dispute reported 06/30/2026 1228755061
Principal investigator 1 PFIZER INC. $43,996.68 05/20/2025 Non-covered Recipient Entity
Prisma Health Cancer Institute
A PHASE 2 BASKET STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB IN SUBJECTS WITH PREVIOUSLY TREATED LOCALLYADVANCED UNRESECTABLE OR METASTATIC SOLID TUMORS DRIVEN BY HER2 ALTERATIONS No dispute reported 06/30/2026 1228755812
Principal investigator 1 PFIZER INC. $21,880.00 05/19/2025 Covered Recipient Teaching Hospital
Ghs Greenville Memorial Hospital
A PHASE 2 BASKET STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB IN SUBJECTS WITH PREVIOUSLY TREATED LOCALLYADVANCED UNRESECTABLE OR METASTATIC SOLID TUMORS DRIVEN BY HER2 ALTERATIONS No dispute reported 06/30/2026 1228756704
Principal investigator 1 PFIZER INC. $43,996.68 05/19/2025 Covered Recipient Teaching Hospital
Ghs Greenville Memorial Hospital
A PHASE 2 BASKET STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB IN SUBJECTS WITH PREVIOUSLY TREATED LOCALLYADVANCED UNRESECTABLE OR METASTATIC SOLID TUMORS DRIVEN BY HER2 ALTERATIONS No dispute reported 06/30/2026 1228757865
Principal investigator 1 Coherus Oncology, Inc. $21,700.00 05/13/2025 Covered Recipient Teaching Hospital
Ghs Greenville Memorial Hospital
CHS11402 No dispute reported 06/30/2026 1235252517
Principal investigator 1 Ipsen Bioscience Inc. $1,282.00 04/04/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
An Open-label, Randomised, Multicentre, Phase III Study of Irinotecan Liposome Injection, Oxaliplatin, 5-fluorouracil/Leucovorin Versus Nab-paclitaxel Plus Gemcitabine in Subjects Who Have Not Previously Received Chemotherapy for Metastatic Adenocarcinoma of the Pancreas No dispute reported 06/30/2026 1176544941
Principal investigator 1 PFIZER INC. $21,998.34 03/20/2025 Non-covered Recipient Entity
Prisma Health Cancer Institute
A PHASE 2 BASKET STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB IN SUBJECTS WITH PREVIOUSLY TREATED LOCALLYADVANCED UNRESECTABLE OR METASTATIC SOLID TUMORS DRIVEN BY HER2 ALTERATIONS No dispute reported 06/30/2026 1228755000
Principal investigator 1 PFIZER INC. $12,467.36 03/20/2025 Non-covered Recipient Entity
Prisma Health Cancer Institute
A PHASE 2 BASKET STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB IN SUBJECTS WITH PREVIOUSLY TREATED LOCALLYADVANCED UNRESECTABLE OR METASTATIC SOLID TUMORS DRIVEN BY HER2 ALTERATIONS No dispute reported 06/30/2026 1228755901
Principal investigator 1 Ipsen Biopharmaceuticals, Inc $9,651.33 03/19/2025 Covered Recipient Teaching Hospital
Oconee Memorial Hospital
A Phase II Study of Tazemetostat in Solid Tumors Harboring an ARID1A Mutation No dispute reported 06/30/2026 1184285759
Principal investigator 1 PFIZER INC. $12,467.36 03/19/2025 Covered Recipient Teaching Hospital
Ghs Greenville Memorial Hospital
A PHASE 2 BASKET STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB IN SUBJECTS WITH PREVIOUSLY TREATED LOCALLYADVANCED UNRESECTABLE OR METASTATIC SOLID TUMORS DRIVEN BY HER2 ALTERATIONS No dispute reported 06/30/2026 1228757203
Principal investigator 1 PFIZER INC. $21,998.34 03/19/2025 Covered Recipient Teaching Hospital
Ghs Greenville Memorial Hospital
A PHASE 2 BASKET STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB IN SUBJECTS WITH PREVIOUSLY TREATED LOCALLYADVANCED UNRESECTABLE OR METASTATIC SOLID TUMORS DRIVEN BY HER2 ALTERATIONS No dispute reported 06/30/2026 1228758217
Principal investigator 1 Astellas Pharma Global Development $1,246.00 03/07/2025 Covered Recipient Teaching Hospital
Ghs Greenville Memorial Hospital
A Phase 3, Global, Multi-Center, Double-Blind, Randomized, Efficacy Study of Zolbetuximab (IMAB362) Plus CAPOX Compared With Placebo Plus CAPOX as First-line Treatment of Subjects With Claudin (CLDN) 18.2-Positive, HER2-Negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma No dispute reported 06/30/2026 1234179998
Principal investigator 1 PFIZER INC. $6,233.68 02/25/2025 Non-covered Recipient Entity
Prisma Health Cancer Institute
A PHASE 2 BASKET STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB IN SUBJECTS WITH PREVIOUSLY TREATED LOCALLYADVANCED UNRESECTABLE OR METASTATIC SOLID TUMORS DRIVEN BY HER2 ALTERATIONS No dispute reported 06/30/2026 1228755394
Principal investigator 1 PFIZER INC. $43,996.68 02/25/2025 Non-covered Recipient Entity
Prisma Health Cancer Institute
A PHASE 2 BASKET STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB IN SUBJECTS WITH PREVIOUSLY TREATED LOCALLYADVANCED UNRESECTABLE OR METASTATIC SOLID TUMORS DRIVEN BY HER2 ALTERATIONS No dispute reported 06/30/2026 1228758013
Principal investigator 1 PFIZER INC. $43,996.68 02/25/2025 Non-covered Recipient Entity
Prisma Health Cancer Institute
A PHASE 2 BASKET STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB IN SUBJECTS WITH PREVIOUSLY TREATED LOCALLYADVANCED UNRESECTABLE OR METASTATIC SOLID TUMORS DRIVEN BY HER2 ALTERATIONS No dispute reported 06/30/2026 1228758017
Principal investigator 1 PFIZER INC. $6,233.68 02/25/2025 Non-covered Recipient Entity
Prisma Health Cancer Institute
A PHASE 2 BASKET STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB IN SUBJECTS WITH PREVIOUSLY TREATED LOCALLYADVANCED UNRESECTABLE OR METASTATIC SOLID TUMORS DRIVEN BY HER2 ALTERATIONS No dispute reported 06/30/2026 1228758191
Principal investigator 1 PFIZER INC. $6,233.68 02/24/2025 Covered Recipient Teaching Hospital
Ghs Greenville Memorial Hospital
A PHASE 2 BASKET STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB IN SUBJECTS WITH PREVIOUSLY TREATED LOCALLYADVANCED UNRESECTABLE OR METASTATIC SOLID TUMORS DRIVEN BY HER2 ALTERATIONS No dispute reported 06/30/2026 1228720041
Principal investigator 1 PFIZER INC. $43,996.68 02/24/2025 Covered Recipient Teaching Hospital
Ghs Greenville Memorial Hospital
A PHASE 2 BASKET STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB IN SUBJECTS WITH PREVIOUSLY TREATED LOCALLYADVANCED UNRESECTABLE OR METASTATIC SOLID TUMORS DRIVEN BY HER2 ALTERATIONS No dispute reported 06/30/2026 1228756707
Principal investigator 1 PFIZER INC. $43,996.68 02/20/2025 Covered Recipient Teaching Hospital
Ghs Greenville Memorial Hospital
A PHASE 2 BASKET STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB IN SUBJECTS WITH PREVIOUSLY TREATED LOCALLYADVANCED UNRESECTABLE OR METASTATIC SOLID TUMORS DRIVEN BY HER2 ALTERATIONS No dispute reported 06/30/2026 1228743565
Principal investigator 1 PFIZER INC. $6,233.68 02/20/2025 Covered Recipient Teaching Hospital
Ghs Greenville Memorial Hospital
A PHASE 2 BASKET STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB IN SUBJECTS WITH PREVIOUSLY TREATED LOCALLYADVANCED UNRESECTABLE OR METASTATIC SOLID TUMORS DRIVEN BY HER2 ALTERATIONS No dispute reported 06/30/2026 1228754983
Principal investigator 1 PFIZER INC. $12,467.36 01/14/2025 Non-covered Recipient Entity
Prisma Health Cancer Institute
A PHASE 2 BASKET STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB IN SUBJECTS WITH PREVIOUSLY TREATED LOCALLYADVANCED UNRESECTABLE OR METASTATIC SOLID TUMORS DRIVEN BY HER2 ALTERATIONS No dispute reported 06/30/2026 1228758834
Principal investigator 1 PFIZER INC. $21,998.34 01/14/2025 Non-covered Recipient Entity
Prisma Health Cancer Institute
A PHASE 2 BASKET STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB IN SUBJECTS WITH PREVIOUSLY TREATED LOCALLYADVANCED UNRESECTABLE OR METASTATIC SOLID TUMORS DRIVEN BY HER2 ALTERATIONS No dispute reported 06/30/2026 1228759165
Principal investigator 1 PFIZER INC. $21,998.34 01/13/2025 Covered Recipient Teaching Hospital
Ghs Greenville Memorial Hospital
A PHASE 2 BASKET STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB IN SUBJECTS WITH PREVIOUSLY TREATED LOCALLYADVANCED UNRESECTABLE OR METASTATIC SOLID TUMORS DRIVEN BY HER2 ALTERATIONS No dispute reported 06/30/2026 1228754553
Principal investigator 1 PFIZER INC. $12,467.36 01/13/2025 Covered Recipient Teaching Hospital
Ghs Greenville Memorial Hospital
A PHASE 2 BASKET STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB IN SUBJECTS WITH PREVIOUSLY TREATED LOCALLYADVANCED UNRESECTABLE OR METASTATIC SOLID TUMORS DRIVEN BY HER2 ALTERATIONS No dispute reported 06/30/2026 1228754598